Singapore-based medtech firm Us2.ai has received the CE Mark for Us2.v1, an automated decision support tool for echocardiography.
The company received U.S. Food and Drug Administration clearance in 2021 and Health Sciences Authority Singapore clearance in 2022. Us2.v1 is now available for clinical use in the U.K. and across Europe, the U.S., Canada, Australia, New Zealand, and Singapore.
Us2.v1 is an automated clinical workflow application with the ability to recognize and analyze 2D and Doppler echo images for comprehensive measurements needed for diagnosis, prediction, and prognosis of heart disease and pulmonary hypertension.
